Prospective study of methylenetetrahydrofolate reductase (MTHFR) variant C677T and risk of all-cause and cardiovascular disease mortality among 6000 US adults

American Journal of Clinical Nutrition

Volumn 95, Issue 5, 2012, Pages 1245-1253

  Yang, Quanhe ^a   Bailey, Lynn ^b   Clarke, Robert ^c   Flanders, W Dana ^d   Liu, Tiebin ^a   Yesupriya, Ajay ^a   Khoury, Muin J ^a   Friedman, Jan M ^e  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; ETHNICITY; FEMALE; FLOUR; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; UNITED STATES;

ADULT; CARDIOVASCULAR DISEASES; ETHNIC GROUPS; FEMALE; FLOUR; FOLIC ACID; FOLLOW-UP STUDIES; FOOD, FORTIFIED; HOMOCYSTEINE; HOMOZYGOTE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84860285767     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.111.022384     Document Type: Article

References (48)

1. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005;365:224-32. (Pubitemid 40138016)
2. Homocysteine Lowering Trialists Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a metaanalysis of the randomized trials. Am J Clin Nutr 2005;82:806-12.
3. Lewis SJ, Ebrahim S, Davey SG. Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005;331:1053.
4. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 2006;333:1114-7. (Pubitemid 44863652)
5. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L, Xu X. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007;369:1876-82. (Pubitemid 46829358)
6. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H, Friedman JM. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006;113:1335-43. (Pubitemid 43739455)
7. Bønaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
8. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354: 1567-77.
9. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG,Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75. (Pubitemid 38500310)
10. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008; 299:2027-36. (Pubitemid 351656584)
11. Ebbing M, Bleie O, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, Refsum H, Pedersen EK, Nygard O. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008;300: 795-804.
12. Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Sleight P, Peto R, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010;303:2486-94.
13. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023-31. (Pubitemid 35204693)
14. Yang QH, Botto LD, Gallagher M, Friedman JM, Sanders CL, Koontz D, Nikolova S, Erickson JD, Steinberg K. Prevalence and effects of gene-gene and gene-nutrient interactions on serum folate and serum total homocysteine concentrations in the United States: findings from the third National Health and Nutrition Examination Survey DNA Bank. Am J Clin Nutr 2008;88:232-46. (Pubitemid 351988705)
15. Roest M, van der Schouw YT, Grobbee DE, Tempelman MJ, de Groot PG, Sixma JJ, Banga JD. Methylenetetrahydrofolate reductase 677 C/T genotype and cardiovascular disease mortality in postmenopausal women. Am J Epidemiol 2001;153:673-9. (Pubitemid 32250975)
16. Arnett DK, Baird AE, Barkley RA, Basson CT, Boerwinkle E, Ganesh SK, Herrington DM, Hong Y, Jaquish C, McDermott DA, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007;115:2878-901. (Pubitemid 46869676)
17. Boccia S, Brand A, Brand H, Ricciardi G. The integration of genome- based information for common diseases into health policy and healthcare as a major challenge for Public Health Genomics: the example of the methylenetetrahydrofolate reductase gene in non-cancer diseases. Mutat Res 2009;667:27-34.
18. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202.
19. Heijmans BT, Gussekloo J, Kluft C, Droog S, Lagaay AM, Knook DL, Westendorp RG, Slagboom EP. Mortality risk in men is associated with a common mutation in the methylene-tetrahydrofolate reductase gene (MTHFR). Eur J Hum Genet 1999;7:197-204. (Pubitemid 29150230)
20. Winkelmayer WC, Kramar R, Sunder-Plassmann G, Fodinger M. Effects of single-nucleotide polymorphisms in MTHFR and MTRR on mortality and allograft loss in kidney transplant recipients 1. Kidney Int 2005;68:2857-62. (Pubitemid 43251033)
21. Rothman KJ, Greenland S. Modern epidemiology. Philadelphia, PA: Lippincott-Raven, 1998.
22. Davey Smith G, Ebrahim S. What can Mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ 2005;330:1076-9. (Pubitemid 40646565)
23. Centers for Disease Control and Prevention. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. Vital Health Stat 1 1994;Jul:1-407.
24. Raiten DJ, Fisher KD. Assessment of folate methodology used in the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994). J Nutr 1995;125:1371S-98S.
25. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987;422:43-52. (Pubitemid 17167357)
26. Selhub J, Jacques PF, Rosenberg IH, Rogers G, Bowman BA, Gunter EW, Wright JD, Johnson CL. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999;131:331-9. (Pubitemid 29424626)
27. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997;145:72-80. (Pubitemid 27009060)
28. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc, B 1995;57:289-300.
29. Schoenfeld D. Partial residuals for the proportional hazards regresssion model. Biometrika 1982;69:239-41.
30. Shah VBBB, Bieler GS. SUDAAN user's manual, release 9. Research Triangle Park, NC: Research Triangle Institute, 2005.
31. Brattström L, Wilcken DEL, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease - the result of a meta-analysis. Circulation 1998;98:2520-6. (Pubitemid 29001189)
32. de Bree A, Verschuren WMM, Bjorke-Monsen AL, van der Put NMJ, Heil SG, Trijbels FJM, Blom HJ. Effect of the methylenetetrahydrofolate reductase 677C→J mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am J Clin Nutr 2003;77:687-93. (Pubitemid 36258581)
33. Guéant-Rodriguez RM, Gueant JL, Debard R, Thirion S, Hong LX, Bronowicki JP, Namour F, Chabi NW, Sanni A, Anello G, et al. Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: a comparative study in Mexican,West African, and European populations. Am J Clin Nutr 2006;83:701-7. (Pubitemid 44699219)
34. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9. (Pubitemid 26006560)
35. de Bree A, Verschuren WM, Blom HJ, Nadeau M, Trijbels FJ, Kromhout D. Coronary heart disease mortality, plasma homocysteine, and B-vitamins: a prospective study. Atherosclerosis 2003;166:369-77. (Pubitemid 36071696)
36. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996;275:1893-6. (Pubitemid 26196449)
37. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, Hennekens C, Stampfer MJ. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998;279:359-64.
38. Voutilainen S, Rissanen TH, Virtanen J, Lakka TA, Salonen JT. Low dietary folate intake is associated with an excess incidence of acute coronary events: the Kuopio Ischemic Heart Disease Risk Factor Study. Circulation 2001;103:2674-80. (Pubitemid 32538781)
39. Voutilainen S, Virtanen JK, Rissanen TH, Alfthan G, Laukkanen J, Nyyssonen K, Mursu J, Valkonen VP, Tuomainen TP, Kaplan GA, et al. Serum folate and homocysteine and the incidence of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr 2004;80:317-23. (Pubitemid 41080004)
40. Kalin SR, Rimm EB. Folate and vascular disease: epidemiological perspective. In: Bailey LB, ed. Folate in health and disease. 2nd ed. Boca Raton, FL: Taylor & Francis, 2009:263-90.
41. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bonaa KH, Spence JD, Nygard O, Jamison R, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010;170:1622-31.
42. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011;123:e18-209.
43. Kauwell GPA, Diaz ML, Yang Q, Bailey LB. Folate: recommended intakes, consumption, and status. In: Bailey LB, ed. Folate in health and disease. 2nd ed. Boca Raton, FL: Taylor & Francis, 2009:467-90.
44. Pfeiffer CM, Johnson CL, Jain RB, Yetley EA, Picciano MF, Rader JI, Fisher KD, Mulinare J, Osterloh JD. Trends in blood folate and vitamin B-12 concentrations in the United States, 1988 2004. Am J Clin Nutr 2007;86:718-27. (Pubitemid 47435840)
45. Tsai MY, Loria CM, Cao J, Kim Y, Siscovick D, Schreiner PJ, Hanson NQ. Clinical utility of genotyping the 677C.T variant of methylenetetrahydrofolate reductase in humans is decreased in the post-folic acid fortification era. J Nutr 2009;139:33-7.
46. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27:1133-63. (Pubitemid 351395448)
47. Glynn RJ. Promises and limitations of mendelian randomization for evaluation of biomarkers. Clin Chem 2010;56:388-90.
48. Clarke R, Bennett DA, Parish S, Verhoef P, Dötsch-Klerk M, Lathrop M, Xu P, Nordestgaard BG, Holm H, Hopewell JC, et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PloS Med 9(2):e1001177 (Epub 21 February 2012).